
Neurointerventional Medical Device Developer
According to the Zhicheng Finance APP, HeartCare-B (06609) rose over 11% in early trading. As of the time of writing, it was up 7.78%, trading at HK$59.6, with a turnover of HK$9.8561 million.
On the news front, HeartCare announced good earnings. The Group expects to achieve a net profit attributable to shareholders of no less than RMB 40 million for the six months ended June 30, 2025, turning a loss into a profit year-on-year. This is mainly due to the Group's business growth, which led to an increase in revenue compared to the corresponding period and a decrease in the Group's overall expense ratio.
In addition, the announcement pointed out that the board recommended using capital reserves to offset losses, subject to shareholder approval by ordinary resolution. The relevant proposal will be submitted to the company's second extraordinary general meeting of shareholders to be held on August 29 for consideration and adoption as an ordinary resolution.